Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamic Study of Oral Mirtoselect in Patients With Suspected Hepatic Disease
2006-004245-42Phase 4Terminated
- Sponsor
- University Hospitals of Leicester NHS Trust
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Mirtoselect Bilberry Extract in hepatic metastasis and hepatic disease (3 arms), sponsored by University Hospitals of Leicester NHS Trust. Primary endpoints: Anthocyanin and metabolite levels in tissues and fluids, Effect on PGE-2 (COX-2 activity) in blood and 1 more. Started Sep 2006; status: terminated.
02
Drugs
Mirtoselect Bilberry Extract
03
Conditions
hepatic metastasishepatic disease
Beyond the preview
Go deeper on 2006-004245-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004245-42.